Iterion Therapeutics Announces Promising Phase 1b Data for Tegavivint in Combination with Osimertinib in First-Line EGFR-Mutated Non-Small Cell Lung Cancer
Combination demonstrating 79% objective response rate (ORR), including complete responses (CRs) in 16% of patients (compared to 1% historically for osimertinib alone) Median progression-free survival (mPFS) of 19.9 months and median overall survival (mOS) of 48.8 months observed in the...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- GRAI acquires Hangout FM to power the next generation of social music streaming
- Re-fined Names Former Assistant Director Marcus Thomas to Board of Directors
- Lisa Price, Tokyo Stylez, Olamide Olowe, Cornell McBride Sr. and More to Be Honored at 2026 Bronner Bros. Beauty Icon Awards
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →